Xencor (XNCR) Q1 2026 earnings snapshot

Xencor (XNCR) opened 2026 with Q1 revenue of US$4.5 million and a basic EPS loss of US$1.71, alongside a net income loss of US$128.9 million that keeps the stock firmly in loss-making territory for now. Over recent quarters, the company has seen revenue move from US$52.8 million in Q4 2024 to US$32.7 million in Q1 2025 and then to US$4.5 million in Q1 2026. Over the same period, quarterly basic EPS moved from a loss of US$0.62 to US$0.66 and then to US$1.71. This sets the stage for investors to focus squarely on how revenue growth potential balances against pressure on margins.

See our full analysis for Xencor.

With the headline numbers on the table, the next step is to set these results against the widely held market stories about Xencor to see which narratives hold up and which ones the latest margin picture starts to question.

Losses widen to US$128.9 million on much lower revenue

• Xencor reported a Q1 2026 net income loss of US$128.9 million on revenue of US$4.5 million, compared with trailing twelve month revenue of US$97.4 million and a trailing twelve month net income loss of US$172.4 million. This quarter therefore carries a much heavier loss than recent quarters on a relatively small top line.
• Bulls focus on the long term, arguing that Xencor's antibody platform and pipeline could support strong revenue growth, yet the recent data create tension with that view:
  • Revenue is forecast to grow at about 35.9% per year, but over the last four reported quarters revenue ranged between US$4.5 million and US$52.8 million. This shows that the current run-rate is still modest against those growth expectations.
  • Reported losses have grown at about 42% per year over the past five years, and the latest quarterly basic EPS loss of US$1.71 versus trailing twelve month basic EPS of US$2.31 in losses underlines how much profitability still needs to improve for the bullish earnings story to play out.

Bulls who think these larger losses are just the cost of building future revenue may want to see how that view is built up across programs and potential markets in the full bullish case for Xencor 🐂 Xencor Bull Case.

Revenue trend and 35.9% growth forecast sit alongside persistent losses

• Trailing twelve month revenue was US$97.4 million compared with individual quarterly revenues of US$52.8 million in Q4 2024, US$32.7 million in Q1 2025 and US$4.5 million in Q1 2026, while trailing twelve month net income stayed in loss territory between US$232.6 million and US$171.1 million over the past six quarters. This indicates that the company is still relying on forecast revenue growth rather than current profitability.
• Analysts' consensus narrative leans on Xencor's differentiated drug design and flexible development platform to support 7.1% annual revenue growth, but the historical loss profile shows the other side of that coin:
  • Consensus expects revenue to reach US$180.3 million and earnings of US$29.0 million to support an analyst price target of US$28.42, compared with current trailing twelve month revenue of US$97.4 million and a trailing twelve month net income loss of US$172.4 million.
  • At the same time, Xencor is currently unprofitable and is not forecast to be profitable over the next three years, so the path from US$172.4 million in trailing twelve month losses to positive earnings depends heavily on both clinical success and revenue growth arriving as expected.

DCF fair value and P/S multiples create a valuation tension

• The stock trades at US$12.31 with a trailing P/S of 9.4x, compared with a DCF fair value estimate of US$149.61 and an analyst price target of US$28.42. The P/S sits slightly below the US Biotechs industry average of 10.9x and marginally above the peer average of 9.2x, so the market price sits at a large discount to the DCF fair value but only a small discount or premium on sales multiples.
• Bears highlight competition, funding risk and prolonged unprofitability, and the current figures give some weight to those concerns:
  • The company is unprofitable and is forecast to remain unprofitable over the next three years, with trailing twelve month net income at a loss of US$172.4 million and basic EPS at a trailing twelve month loss of US$2.31. This helps explain why the stock may trade far below the US$149.61 DCF fair value estimate despite its revenue growth forecast.
  • Even though the price is 91.8% below the DCF fair value estimate, the P/S of 9.4x sits close to biotech peers at 9.2x. The discount to the DCF fair value is therefore not matched by a similar discount on simple sales multiples, which fits with the bearish concern that sustained losses and execution risk could limit how much value the market currently assigns to future pipelines.

For readers who see these valuation gaps as a sign of market caution rather than clear upside, it can be useful to walk through how the cautious case frames competition, funding and prolonged losses in more depth 🐻 Xencor Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xencor on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of losses, forecasts and valuation gaps feels mixed to you, that is healthy. Move quickly and weigh the data against the stock's key trade offs by reviewing the 2 key rewards and 2 important warning signs

See What Else Is Out There

Xencor is still reporting sizeable losses on modest revenue and relies heavily on forecasts rather than current profitability, which can add meaningful risk to your portfolio.

If you want ideas that aim to offset that kind of risk with steadier fundamentals, check out the 72 resilient stocks with low risk scores and quickly compare companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.